Searchable abstracts of presentations at key conferences in endocrinology

ea0044p137 | Neoplasia, cancer and late effects | SFEBES2016

The effects of proton pump inhibitor therapy on neuroendocrine tumour biomarkers

Constantinou Christoforos , Hill Neil , Bloom Steve , Murphy Kevin , Bech Paul

Introduction: Neuroendocrine tumours (NETs) comprise a heterogeneous group of tumours that constitute a diagnostic and therapeutic challenge. The most commonly used general NET circulating biomarker is Chromogranin A (CgA). CgA is elevated under other circumstances, notably by the use of Proton Pump Inhibitors (PPIs) and possibly via a gastrin-mediated mechanism. Chromogranin B (CgB) and Cocaine- and Amphetamine-Regulated transcript (CART) are two less commonly used NET biomar...

ea0038p160 | Neoplasia, cancer and late effects | SFEBES2015

Chromogranin B: a possible prognostic biomarker for neuroendocrine tumours?

Wanigasekara Nipuni E Wanniachchi , Bech Paul , Murphy Kevin

Neuroendocrine tumours (NETs) are rare tumours that originate from neuroendocrine cells and their incidence has increased for the last 20 decades; partly because of advances in diagnostic tools, which have improved detection rates. Chromogranin A (CgA) is the most widely used biochemical tumour marker for NETs, however, its prognostic utility has been questioned due to several non-neuroendocrine causes of elevated CgA. This is the first study to assess the prognostic utility o...

ea0082p10 | Poster Presentations | SFEEU2022

Familial hypocalciuric hypercalcaemia or multiple endocrine neoplasia 1? – when assay interference challenges the diagnosis

Vanderpant Natalie , D Boyle Luke , Bech Paul , Mitchell Catherine , Tan Tricia , Morganstein Daniel L

Case history: An asymptomatic 26-year-old female was found to have hypercalcaemia with an associated normal PTH and vitamin D deficiency on blood tests in primary care. She was referred to the endocrinology clinic for further assessment. There was no history of renal calculi, constipation or fractures. The patient was taking the combined oral contraceptive pill only. There was a family history of hypercalcaemia, with an uncle affected in his 50s and a first cousin in his 20s. ...

ea0081oc7.2 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Kisspeptin administration has therapeutic potential for men with low sexual desire by increasing penile tumescence and sexual brain processing

Mills Edouard , Ertl Natalie , Wall Matt B , Thurston Layla , Yang Lisa , Suladze Sofiya , Hunjan Tia , Phylactou Maria , Patel Bijal , Muzi Beatrice , Ettehad Dena , Howard Jonathan , Rabiner Eugenii A , Bech Paul , Abbara Ali , Goldmeier David , Comninos Alexander , Dhillo Waljit

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with dysfunctional brain activation in regions governing sexual responses, resulting in a deficiency/absence of sexual desire with marked distress. It affects up to 8% of men with detrimental effects on quality of life, interpersonal relationships and fertility, but so far has no licensed treatment options. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role ...

ea0081p183 | Reproductive and Developmental Endocrinology | ECE2022

Intranasal kisspeptin administration stimulates reproductive hormone secretion in healthy volunteers and patients with hypogonadism

Mills Edouard , Swedrowska Magda , Thurston Layla , Phylactou Maria , Patel Bijal , Yang Lisa , Clarke Sophie , Muzi Beatrice , Alexander Emma , Choudhury Muhammad , Bech Paul , Abbara Ali , Forbes Ben , Comninos Alexander , Dhillo Waljit

Background: Kisspeptin is a critical activator of hypothalamic gonadotrophin releasing hormone (GnRH) neurons and has significant potential to treat common reproductive disorders. To date, kisspeptin has solely been administered to humans via the intravenous or subcutaneous routes, however intranasal administration could offer a novel non-invasive delivery route. We therefore sought to determine the effects of intranasal kisspeptin on reproductive hormone release in humans for...

ea0081p445 | Reproductive and Developmental Endocrinology | ECE2022

Kisspeptin improves sexual brain processing in women with low sexual desire

Thurston Layla , Hunjan Tia , Ertl Natalie , B Wall Matt , Mills Edouard , Suladze Sofiya , Patel Bijal , Alexander Emma , Muzi Beatrice , A Rabiner Eugenii , Bech Paul , Goldmeier David , Abbara Ali , Comninos Alexander , Dhillo Waljit

Introduction: Sexual desire is a key component of the sexual response model. Absence or deficiency of sexual desire can lead to marked distress or interpersonal difficulty, termed ‘hypoactive sexual desire disorder’ (HSDD). HSDD is the most common female sexual health complaint worldwide, affecting up to 10% of women. Despite its detrimental impact on psychological well-being and quality of life, treatment options are currently limited. The hormone kisspeptin is a ke...

ea0086oc3.6 | Reproductive and Neuroendocrinology | SFEBES2022

Kisspeptin enhances sexual and attraction brain processing in women with low sexual desire

Thurston Layla , Hunjan Tia , Ertl Natalie , Wall Matthew , Mills Edouard , Suladze Sofiya , Patel Bijal , Alexander Emma , Muzi Beatrice , Bassett Paul , Rabiner Eugenii , Bech Paul , Goldmeier David , Abbara Ali , Comninos Alexander , Dhillo Waljit

Hypoactive sexual desire disorder (HSDD) is a persistent lack of sexual desire, causing marked interpersonal distress. It is the most common global female sexual health problem, although the precise pathophysiology remains uncertain. Existing treatment options are limited by their efficacy and side effects. The neuropeptide kisspeptin offers a potential therapeutic target given its emerging role in modulating reproductive behaviour. Using a combination of psychometric, neuroim...

ea0065op5.4 | Reproductive Endocrinology and Biology | SFEBES2019

Kisspeptin as a novel biomarker for pregnancy complications

Phylactou Maria , Abbara Ali , Al-Memar Maya , Eng Pei Chia , Comninos Alexander N , Izzi-Engbeaya Chioma , Clarke Sophie A , Mills Edouard , Nadir Rans , Sykes Mark , Pacuszka Ewa , Yang Lisa , Fourie Hanine , Bech Paul , Kelsey Tom W , Bourne Tom , Dhillo Waljit S

Background: Placentation (invasion of the placenta into the maternal endometrium) is hypothesised to be critical for healthy placental function and is abnormal in two thirds of miscarriages. Kisspeptin has emerged as a putative regulator of physiological placentation; it is highly expressed in placental syncytiotrophoblasts and could play an important paracrine role in the regulation of placentation. Circulating kisspeptin levels are considerably raised during healthy pregnanc...

ea0070oc9.2 | Reproductive and Developmental Endocrinology | ECE2020

Kisspeptin as a biomarker for pregnancy complications

Phylactou Maria , Abbara Ali , Chia Eng Pei , Al-Memar Maya , Comninos Alexander , Nadir Rans , Izzi-Engbeaya Chioma , Clarke Sophie , Mills Edouard , Sykes Mark , Pacuszka Ewa , Yang Lisa , Fourie Hanine , Bech Paul , Kelsey Tom , Bourne Tom , Dhillo Waljit

Background: Placentation (invasion of the placenta into the maternal endometrium of pregnancy known as the decidua) is hypothesised to be critical for healthy placental function and is abnormal in two thirds of miscarriage. Kisspeptin has emerged as a putative regulator of physiological placentation; it is highly expressed in placental syncitio-trophoblasts, whereas its receptor is expressed in both syncitio- and cyto-trophoblasts, such that kisspeptin is hypothesized to play ...

ea0086op3.1 | Reproductive and Neuroendocrinology | SFEBES2022

Kisspeptin enhances penile tumescence and sexual brain processing in men with low sexual desire

Mills Edouard G , Ertl Natalie , Wall Matt B , Thurston Layla , Yang Lisa , Suladze Sofiya , Hunjan Tia , Phylactou Maria , Patel Bijal , Muzi Beatrice , Ettehad Dena , Bassett Paul A , Howard Jonathan , Rabiner Eugenii A , Bech Paul , Abbara Ali , Goldmeier David , Comninos Alexander N , Dhillo Waljit S

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with a deficiency of sexual desire with marked distress. It affects up to 8% of men, but has no licensed treatments. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role in modulating reproductive behaviour in animal models and healthy men. However, there are no studies examining its effects in HSDD. To address this, we performed the first clinical study of ki...